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STRATEGIES TO TARGET SYNOVITIS
A broad range of strategies to target inflammatory synovitis is
currently being explored. Most approaches require the identi-
fication of a single molecule/pathway that is tractable to
modulation in the clinic. In general, molecular activities with
relevant biological effects are sought within the appropriate
target lesion—namely, the synovium. Thereafter, such an
activity may be targeted in rodent models of arthritis and the
effects on inflammation and articular destructionmeasured.A
moiety with plausible biology and bioactivity in model
systems may then move to phase I “proof of concept” studies
and thereafter to clinical development (fig 1). The successful
targeting of tumour necrosis factor α (TNFα) represents an
example of such an approach whereby an effective therapeu-
tic agent has been derived.1 2 However, even after TNF
blockade, unmet clinical need clearly persists in inflammatory
arthritis.Major challenges remain, in particular the identifica-
tion of therapeutic responders a priori, and the rational choice
of additional targets, either as independent primary therapeu-
tic targets or as synergistic biological targets for future combi-
nation applications. This short review will test interleukin 15
(IL15) in this model of new biological development to evalu-
ate its therapeutic potential. Thereafter, an alternative
approach will be considered for comparative purposes,
whereby a model in which multiple pathways within the syn-
ovium are targeted simultaneously using a strategy borrowed
from the host-parasite relationship arising from evolutionary
pressures over millennia (fig 1).
INTERLEUKIN 15 AS A THERAPEUTIC TARGET
Our group has recently sought mechanisms whereby innate
and acquired immune responses interact during chronic
inflammation, with particular emphasis on cytokine biology.
Many cytokines present within the synovium derive from
macrophages and synovial fibroblasts.3 IL15, a cytokine with
structural similarities to IL2,4 is produced primarily by macro-
phages and as such attracted our attention at an early stage as
a potential regulator of synovial inflammation. It is now clear
that IL15 exhibits plausible biological effector function, is
detectable in inflamed synovial tissues and, finally, when sup-
pressed in rodent models of articular inflammation offers
therapeutic utility.
Plausible biology
IL15 mRNA is broadly expressed throughout numerous
normal human tissues and cell types, including activated
monocytes, dendritic cells, and fibroblasts.4 5 IL15 mRNA
expression, however, is not synonymous with protein detec-
tion in tissues, reflecting tight regulatory control of translation
and secretion. IL15 is subject to significant post-
transcriptional regulation via 5’-UTR AUG triplets, 3’ regula-
tory elements, and a further putative C-terminus region regu-
latory site. Two isoforms of IL15 subject to altered
glycosylation are thus generated—secreted IL15 (48-aa) from
a long signalling peptide and an intracellular IL15 form local-
ised to non-endoplasmic regions in both cytoplasmic and
nuclear compartments from a short signalling peptide (21-
aa).5 Cell membrane expression may be crucial in mediating
extracellular function rather than secretion and, in part,
explains the difficulty in detecting soluble IL15 in biological
systems.
Factors that drive endogenous IL15 release are as yet poorly
understood. Exogenous agents include human herpesvirus 6
and 7,Mycobacterium leprae,Mycobacterium tuberculosis, Staphylo-
coccus aureus, lipopolysaccharide, and ultraviolet irradiation.
IL15 binds a widely distributed heterotrimeric receptor
(IL15R) which consists of a β-chain (shared with IL2) and
common γ-chain, together with a unique α-chain (IL15α),
that in turn exists in eight isoforms.5 Subsequent signalling is
through at least JAK1/3 and STAT3/5. Additional signalling
through src related tyrosine kinases and Ras/Raf/MAPK to
fos/jun activation is also proposed. High affinity (1011 M−1)
with slow off-rate make IL15Ra in soluble form a useful and
specific inhibitor in biological systems. IL15 exhibits broad
proinflammatory effects that are summarised in fig 2. The tar-
get cells described are of relevance to current models of syno-
vitis pathogenesis. Of particular importance may be its ability
to initiate and sustain T cell chemokinesis, functional
polarisation, cognate interactions with macrophages and
memory compartment maintenance, NK cell activation, and
neutrophil effector function. Details of these and broader
effects have recently been reviewed.6
Plausible expression profile
IL15 mRNA (Taqman PCR, nested reverse transcriptase-
polymerase chain reaction (RT-PCR)) and protein (immuno-
histochemistry, enzyme linked imunosorbent assay (ELISA),
receptor capture assay) are detected in rheumatoid arthritis
(RA) synovial membrane at higher levels than in reactive
arthritis or psoriatic synovial biopsy specimens.7 Low levels of
IL15 are also present in sera of up to 40% of patients with RA,
although variable levels have been reported in distinct
populations.8 Serum IL15 expression does not correlate with
disease subsets thus far recognised. Whereas RA serum TNFα
levels correlate with the presence of germinal centres in paral-
lel synovial biopsies, IL15 levels were raised, with either
germinal centres or diffuse lymphocytic infiltrative patterns.9
IL15 expression has also recently been detected in synovial
membrane derived from patients with juvenile rheumatoid
arthritis,10 associated with IL18, IL12, and interferon γ (IFNγ)
expression. Spontaneous production of IL15 by primary RA
synovial membrane cultures and by isolated synovial fibro-
blasts is reported.11 In long term cultures of synovial tissues,
outgrowth was found to be dependent upon the presence of T
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cells, which in turn lead to local release of IL15, IL17, and
fibroblast growth factor-1.12 Factors that in turn drive synovial
IL15 expression are unclear. Activated T cells can induce IL15
expression in macrophages by cognate interactions. Exposure
of synovial fibroblasts to TNFα or IL1β also induces high lev-
els of IL15 expression, although rarely in secreted form. In
dermal fibroblasts TNFα but not IFNγ induces membrane
expression of IL15, which in turn can sustain T cell growth. A
further pathway promoting IL15 production has been
suggested in studies of synovial embryonic growth factor
expression through the wingless 5 and frizzled 5 ligand pair.13
Thus IL15 is detected in synovial tissues, as are factors that can
initiate and sustain its expression.
Effector function of IL15 in synovium is largely predicted
from its basic biology. Its effects in synovial tissues have been
recently reviewed.8 In particular, IL15 sustains T cell/
macrophage interactions to promote activation and cytokine
release by the latter. Similar interactions between T cells and
fibroblast-like synoviocytes with endogenous positive feed-
back loops have also been demonstrated. Of interest, secreted
IL15 was not detected, indicating that functionally active
membrane IL15 may be involved. IL15 can also promote T cell
migration and survival, NK cell activation, synovial neutrophil
activation and survival. Complex networks involving secreted
and cognate pathways are therefore predicted in which
cytokine secretion and adhesion molecule expression interact
to sustain chronic leucocyte activation. IL15 apparently oper-
ates as a critical factor in these pathways, probably in synergy
with other locally release cytokines including TNFα, IL18,
IL12, and IL6.14
Successful targeting in vivo in models
Three approaches have been considered to block IL15—
namely, neutralising antibodies, soluble interleukin 1 receptor
Figure 1 Alternative model
approaches, resulting in “proof of
concept” clinical studies to target
synovitis.
Figure 2 IL15 exhibits pleiotropic
effects on numerous target cell types
involved in current models of synovitis
pathogenesis.
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antagonist (IL15Ra), and mutated IL15 species, usually
generated as fusion proteins. Several studies using these
diverse approaches have been attempted, or are in progress.
Full length soluble IL15Ra administration can suppress devel-
opment of collagen induced arthritis (CIA), associated with
delayed development of anticollagen-specific antibodies
(IgG2a) and with reduced antigen-specific cytokine release.15
Studies are continuing to determine whether small molecule
derivatives of soluble IL15Ra are of therapeutic use in the CIA
model. An alternative approach has been to generate mutant
IL15 forms that can specifically modify IL15 activities. An
IL15/Fcγ2a fusion protein that antagonises the activities of
IL15 in vitro, suppresses the onset of delayed-type hypersensi-
tivity responses in vivo associated with reduction in CD4+ T
cell infiltration.16 This fusion protein has also proved effective
in vivo in preventing rejection of murine islet cell allografts in
combination with CTLA4/Fc.17
IL15—proof of concept?
The foregoing data suggest that IL15 has many features of
an attractive therapeutic target in inflammatory synovitis. A
fully human monoclonal anti-IL15 monoclonal antibody has
recently been generated that neutralises human IL15 (HuMax-
IL15). Preliminary analysis of data arising from a phase I, dose
ascending safety and tolerability study performed in Europe
suggests that IL15 can be neutralised safely with no immediate
effects on leucocyte subsets, and with no significant short term
clinical toxicity. Moreover, American College of Rheumatology
20 (ACR20), ACR50, and ACR70 responses were of the same
order as those achieved in studies using TNF blocking agents as
monotherapy.18 These data must, however, be interpreted with
caution because no placebo control was included throughout
the experimental design; phase II data are awaited.
Nevertheless, the study does provide early proof of concept that
the above model can be useful in detecting therapeutic targets,
with promise for subsequent intervention studies.
TARGETING MULTIPLE PATHWAYS—LESSONS FROM
HOST-PARASITE SYMBIOSIS
An alternative strategy for the detection of individual molecules
as targets is reflected in recent observations, in which the
autoimmune therapeutic potential of parasite derived moieties
has been explored. Such an approach facilitates targeting
multiple points in the inflammatory cascade but relies on
host-parasite symbiosis to prevent excess host immune
suppression. This idea will be briefly explored using as an
example the filarial nematode Acanthocheilonema viteae.
Understanding modulation of the host immune system by
pathogens offers rich therapeutic potential because evolution-
ary pressures operate over millennia to promote “safe”
immune modulation. Parasitic filarial nematodes are often
tolerated in human hosts for decades with little evidence of
host disease, and this seems to reflect parasite induced
suppression of host proinflammatory immune responses. Har-
nett et al previously described a filarial nematode derived,
secreted phosphorylcholine-containing glycoprotein, ES-62,
with immunomodulatory activities that are broadly anti-
inflammatory in nature.19 Filarial nematodes, arthropod
transmitted parasites of vertebrates including humans,
achieve long term infection through suppression or modula-
tion of the host immune system. In infected humans, reduced
production of IFNγ and increased production of IL4/IL10
together with raised IgG4 levels suggest a predominant
Th2/anti-inflammatory phenotype conducive to both parasite
survival and host health.20 21 Consistent with this, most
humans who harbour viable filarial nematodes exhibit little
parasite induced inflammatory response or local tissue
destruction/disruption.
In recent studies we showed that a secreted product of A
viteae, ES-62, significantly reduced initiation of inflammatory
arthritis in the CIA model in DBA/1 mice.22 Crucially, ES-62
was also found to suppress CIA severity and progression when
administration was delayed until after clinically evident
disease onset. Ex vivo analyses showed that in both cases, the
effects were associated with inhibition of collagen-specific
proinflammatory/Th1 cytokine (TNFα, IL6, and IFNγ) release.
ES-62 was found also to significantly suppress human macro-
phage activation through cognate interaction with activated T
cells, and to suppress lipopolysaccharide induced rheumatoid
arthritis synovial TNFα and IL6 production. Although of a
preliminary nature, these data provide intriguing proof of
concept that parasite derived molecules, or derivatives thereof
might be used therapeutically borne out of the long necessity
for “tolerable” immune subversion.
CONCLUSIONS
In this short summary I have illustrated two distinct strategies
for targeting chronic inflammation in inflammatory arthritis.
The genome and proteomic revolution are already yielding
numerous additional “targets” for consideration in the preclin-
cial development. “Biological” versus “small molecule” inhibi-
tory approaches are currently debated in the main. The data
shown above would argue for a broader discussion, in which
consideration is given not only to new, single target identifica-
tion but also to development of new strategies, using elucida-
tion of broad mechanisms of immune subversion drawn from
natural examples of successful immune modulation.
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